Needham & Company Reiterates a 'Buy' on Gilead Sciences (GILD); Q2 Beats; Management Maps Out Phase 3 GS-7977 Plans
Tweet Send to a FriendGet Alerts GILD Hot Sheet
Price: $55.63 +0.27%
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 13
Rating Summary:
17 Buy, 6 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 15 | New: 13
Trade GILD Now!
Needham & Company reiterates a 'Buy' on Gilead Sciences (NASDAQ: GILD) price target of $56.00.
Analyst, Alan Carr, said, "Gilead reported $2.41B (+12.5% y/y) in total revenues yesterday, above our and consensus expectations for $2.27B and $2.23B. Strong antiviral sales were driven by continuing inventory build by states through ADAP. Non-GAAP EPS of $0.99 (-1.1% y/y) exceeded our $0.94 and consensus $0.95 estimates. Management raised 2012 sales guidance by $200M to $8.8-$9.0B, expecting states to work toward further reductions in HIV wait lists this year."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $51.68 yesterday, with a 52 week range of $34.45-$56.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Alan Carr, said, "Gilead reported $2.41B (+12.5% y/y) in total revenues yesterday, above our and consensus expectations for $2.27B and $2.23B. Strong antiviral sales were driven by continuing inventory build by states through ADAP. Non-GAAP EPS of $0.99 (-1.1% y/y) exceeded our $0.94 and consensus $0.95 estimates. Management raised 2012 sales guidance by $200M to $8.8-$9.0B, expecting states to work toward further reductions in HIV wait lists this year."
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $51.68 yesterday, with a 52 week range of $34.45-$56.50.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Jefferies Bumps Zumiez (ZUMZ) Numbers Up, But Remains on Sidelines
- Janney Capital Trims Numbers on Buckle (BKE), Margins Peaking
- Imperial Capital Boosts Price Target on Dick's (DKS); 'Best-of-Breed'
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS ViewRelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
